Vergent Bioscience

company

About

Vergent Bioscience is a biotech company focusing on the development of tumor-targeted molecular imaging molecules for cancer surgery.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$21.50M
Industries
Biotechnology,Health Care,Medical,Medical Device
Founded date
Jan 1, 2016
Number Of Employee
1 - 10
Operating Status
Active

While the complete removal of residual cancer at the tumor margins during the surgical resection of solid tumors is closely linked with improved cure rates, it is often difficult for even experienced surgeons to distinguish cancerous tissue from normal tissue. Visual differentiation is needed at the cellular level.

Vergent's molecularly-targeted imaging molecule, VGT-309, binds to enzymes that are overexpressed in tumor tissue, activating a brightly fluorescing dye. This proprietary molecule can identify and bind to multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. When injected prior to surgery, VGT-309 “lights up” cancerous tissue and gives the surgeon a clear visual guide for the removal procedure.

Vergent’s approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic surgery procedures, while uniquely retaining the pricing flexibility required for success in a value-based healthcare system.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$33.41M
Vergent Bioscience has raised a total of $33.41M in funding over 2 rounds. Their latest funding was raised on Oct 4, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 4, 2022 Series B $21.50M 1 Detail
Jun 12, 2018 Series A $11.91M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Vergent Bioscience is funded by 1 investors. Colle Capital Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Colle Capital Partners Series B